Current through Register Vol. 46, No. 12, March 20, 2024
(a)
Authority and purpose.
The New York State Urban Development Corporation hereby
establishes the New York Fund for Innovation in Research and Scientific Talent
(NYFIRST) Program as a component of the Life Sciences Initiatives Program.
NYFIRST is intended to encourage the recruitment and retention of exceptional
life science researchers and world-class talent at the state's medical schools
to accelerate translational research. The recruited or retained researchers
will demonstrate proven scientific accomplishments and a history of
entrepreneurship and grant funding. NYFIRST funds will be used to support the
establishment or upgrading of laboratories for these researchers, for purchases
of capital equipment and specialized supplies needed for their research, and as
working capital to cover costs of professional staff (including staff
scientists, doctoral students/post-doctoral fellows, and technicians, but
excluding the recruited researcher) critical to the proposed research.
The NYFIRST Program is intended to:
(1) increase the number of patent
applications and patentable discoveries at medical schools and the number of
patents from these schools;
(2)
increase the recruitment/retention rate of medical school faculty focused on
translational research;
(3) enhance
and expand the expertise, qualifications and capabilities residing within these
institutions; and
(4) increase
Federal and philanthropic funding, as well as venture capital funding, to
medical schools awarded NYFIRST grants.
(b)
Definitions.
For the purposes of this section, the terms below shall have
the following meaning:
(1)
Applicant or eligible applicant shall mean a
medical school within the State that applies for NYFIRST assistance.
(2)
Corporation or
ESD shall mean the New York State Urban Development
Corporation doing business as Empire State Development.
(3)
Eligible project shall
mean a project that meets the eligibility criteria set forth in subdivision (d)
of this section.
(4)
Federal assistance shall mean funds available, other than by
loan, from the Federal government, either directly, or through allocation by
the State for program purposes pursuant to any Federal law or
program.
(5)
Life sciences
economic development benefits shall mean the creation, expansion,
enhancement or acceleration of life sciences programs throughout the State that
lead to:
(i) the commercialization of life
sciences in New York State;
(ii)
the creation or retention of jobs in the life sciences industry employing full
time permanent employees;
(iii) the
promotion of the life science ecosystem within a region of the State;
(iv) new patents in life science;
(v) additional commercial laboratory space;
or
(vi) additional venture capital
money for life sciences entities in New York State.
(6)
Match, matching
share, or matching funds shall mean that portion of
the total cost of a project that the grantee must provide, pursuant to
paragraph (c)(2) of this section.
(7)
Medical school shall
mean a public or private medical school in New York State that is accredited by
the liaison committee on medical education or the commission on osteopathic
college accreditation, or such medical school together with an affiliated
entity, located in New York State.
(8)
Principal investigator
shall mean the holder of an independent grant administered by a university and
the lead researcher for the grant project who makes the final decisions and
supervises funding and expenditures on a given research project.
(9)
Project shall mean the
scope of activities supported by a NYFIRST Program grant and the grantee's
matching share.
(10)
Reimbursable expenses shall mean approved costs incurred by
the NYFIRST grantee to perform the project. Reimbursable expenses must be
incurred during the grant term. An item included as a match cannot also be
included as a reimbursable expense.
(11)
Specialized supplies
shall mean consumables, including, but not limited to, antibodies, assay kits,
proteins, reagents, enzymes, DNA/RNA and PCR products, nucleosides and
nucleotides, specialized media, substrates and other bioproducts required to
conduct the research specified.
(12)
Translational research
shall mean research that applies, or translates, existing knowledge about
biology into techniques and tools for treating human disease: translational
research takes knowledge from bench to bedside. This differs from academic
research, which is focused on careful study of a subject or field to discover
facts or principles that are added to the general body of scientific
knowledge.
(c)
Available program assistance.
(1)
The NYFIRST Program makes available financial assistance in the form of grants
to applicants for eligible projects. The maximum grant amount for any eligible
project is $1 million.
(2) Matching
funds. Grantees will be required to provide $2 of matching funds for every $1
of NYFIRST Program assistance. The match is a non-reimbursable component of the
project's total cost and is reflective of the grantee's long-term commitment to
the project.
(i) The match provided by the
grantee may be cash, including Federal assistance, or in-kind services. If
in-kind services any match item may be donated by the grantee or reflect the
grantee's use for the project of such an item donated by a third party (such as
industry or alumni/ae). However, no financial assistance made available to the
grantee by the corporation or any other New York State agency or public
authority may be included as part of any program grantee's match. Nothing in
this subdivision shall prohibit the State University of New York or the City
University of New York from using a portion of their respective operating funds
as match.
(ii) Items eligible to be
approved are matching funds directly related to the purpose of the project
including, but not limited to: compensation for the recruited principal
investigator meeting the eligibility criteria described in paragraph (d)(3) of
this section; financial support for research staff and graduate students who
are members of the newly recruited principal investigator's team; relocation
expenses for the aforementioned principal investigator or associated team;
other expenses as are necessary for recruitment purposes; the cost of preparing
and equipping work space for the principal investigator or associated team;
other expenses required to conduct the relevant research undertaken by the
principal investigator or associated team such as laboratory supplies; and the
cost of new faculty lines in research areas to complement the recruited
principal investigator and his/her team.
(iii) All matching funds must be expended
during the program grant term and where practicable on a pro
rata basis with program grant funding.
(iv) All items identified as matching funds
will be reviewed by the corporation, which will approve such matching funds as
the corporation may determine, in its sole discretion, to be reasonable as to
amount and relation to the project.
(3) Program grant funds will be disbursed on
a semiannual reimbursement basis. Grantees shall submit quarterly invoices
twice yearly with and supporting documentation satisfactory to the corporation,
as work is performed and costs incurred.
(d)
Eligibility criteria.
(1) Program grants are intended to encourage
the recruitment and retention by the State's medical schools of exceptional
life science researchers and world-class talent focused on accelerating
translational research. NYFIRST grants may be used to support the establishment
or upgrading of laboratories for these researchers, for purchases of capital
equipment and specialized supplies needed for their research, and as working
capital to cover costs of professional staff (including staff scientists,
doctoral students/post-doctoral fellows, and technicians, but excluding the
recruited principal investigator) critical to the proposed research.
(2) ESD will make no more than one award per
applicant per application cycle.
(3) The scientific talent recruited or
retained as a principal investigator to head a laboratory must:
(i) demonstrate a record of translational
research with clear potential for commercialization;
(ii) demonstrate that the research to be
undertaken focuses on the development of an innovative solution for an
identified healthcare-related problem, with the potential to result in
significant life sciences economic development benefits in New York
State;
(iii) demonstrate a history
of entrepreneurship such as by patent applications, patent approvals and
commercialization of research and by success in obtaining funding;
(iv) have sufficient funding to support the
project being undertaken for three years;
(v) be tenured or be on a tenure track and
provide sufficient documentation to ESD to corroborate such track;
(vi) hire or retain (or cause to be hired or
retained by the medical school) at least two scientists or doctoral
students/post-doctoral fellows full-time (40hrs/week) or at least four
scientists or doctoral students/post-doctoral fellows who each work a minimum
of 20hrs/week; the scientists and post-doctoral fellows must be recruited from
outside of New York State; and
(vii) be employed by an institution or
company outside New York State at the time an offer of employment is made by
the applicant, or have a verifiable offer from an institution from another
state that would lead him/her to leave New York State. (See paragraph
[e][2][ii] of this section.)
(4) The offer of employment to the principal
investigator by the applicant must be made between the date of availability of
the NYFIRST application for a given application cycle and the application
deadline for that cycle. Acceptance of such offer also must occur between the
date of availability of the NYFIRST application for a given application cycle
and the application deadline for that cycle.
(5) A copy of the accepted employment offer
must be submitted with the NYFIRST application.
(6) The grant term is four years, and all
expenditures for which program funding is approved must be commenced and
completed no more than four years from commencement of the grant. The
corporation, in its sole discretion, may terminate the program grant for any
eligible project that does not adhere to the timelines established in the grant
agreement or otherwise fails to demonstrate satisfactory performance.
(e)
Application
requirements, process and evaluation.
(1) On an application provided by ESD, the
applicant shall provide such information about the applicant, the principal
investigator and the project as ESD may require. The application shall
highlight the following information relevant to the research being undertaken:
unmet clinical need, market potential, and an approximate timeline and
anticipated steps to market/clinical use. There are no restrictions in terms of
therapeutic area of research. The completed application shall illustrate how
the applicant has met the criteria established in paragraph (d)(3) of this
section and also will include details regarding the following:
(i) therapeutic need for the research
e.g., extent of the unmet need for therapeutics, diagnostics
or other intellectual property; what alternatives are already available, market
size, and market environment;
(ii)
anticipated path to commercialization; key milestones to be met as this
research moves toward commercialization;
(iii) uniqueness of the research and
competitive edge;
(iv) summary of
supporting proof of concept data and other relevant research, and
publications;
(v) strength of
principal investigator's intellectual property/entrepreneurial history and
intellectual property potential and patent considerations of proposed
research;
(vi) proposed scope of
work, timeline and the feasibility of timeline;
(vii) profile(s) of the recruited or retained
principal investigator and the proposed team members;
(viii) budget;
(ix) total amount of NIH and other funding
that will accompany the recruited principal investigator as well as his/her
funding history; and
(x)
documentation establishing that the term of employment between the institution
(the grantee) and the principal investigator, as well as each member of the
team accompanying the principal investigator is, at a minimum, for a period
coextensive with the grant term.
(2) The application must also be accompanied
by:
(i) a signed statement of support of the
proposed project executed by the chief executive officer or dean of the
applicant medical school, and in a format approved by the corporation,
recommending the application to the corporation and authorizing an official of
the applicant institution to execute documents necessary for the
project;
(ii) a copy of the dated
and accepted offer letter by the principal investigator, indicating the
specific position offered and tenure status and including agreement on
anticipated commencement of employment. (Confidential information unrelated to
the position, date of offer and signed acceptance may be redacted) or, in the
case of retention of a principal investigator considering an offer from an
institution outside of New York State, a signed statement by the chief
executive officer or dean of the applicant medical school, verifying that the
principal investigator had indicated his/her intention to relocate to another
institution outside of New York State, with details regarding the potential
offer, including position and salary, and that a counteroffer has been made and
accepted. A copy of the counteroffer and of the acceptance of same must be
provided;
(iii) verification that
the recruited principal investigator was employed at an institution from
outside of New York State prior to receipt and acceptance of the offer letter;
and
(iv) such other information as
the corporation may require to implement this program.
(3) To the extent practicable, ESD will
attempt to make awards to as many medical schools as possible within the State,
assuming equivalent qualifying evaluation scores and taking into consideration
regional balance, anticipated job creation and retention and economic
development benefits.
(f)
Selection criteria/scoring.
(1) Applications will be evaluated on the
criteria detailed in subdivision (d) of this section and the documentation
provided pursuant to paragraph (e)(1) of this section on a scale of one to
five, where:
1 = does not meet qualification expectation;
3 = meets qualification expectations; and
5 = exceeds qualification expectations.
(2) Selection criteria will be weighted as
follows:
Criteria Category | Weight |
1. Unmet need | 30% |
2. Novelty & competitiveness of proposed
solution | 30% |
3. Preliminary/supporting data | 15% |
4. Strength of principal investigator's intellectual
property history and patent potential of proposed research | 15% |
5. Feasibility of development
timeline | 10% |
(3)
The corporation intends to make program grant awards through a competitive
grant solicitation to qualifying applicants twice annually until the funds
under this program are fully committed.
(4) For each application cycle, the period
between application availability and the application deadline shall be six
months.
(g)
Eligible uses.
(1) Program
grants must be used for expenses directly related to the eligible project
including but not limited to:
(i) costs
relating to the design, acquisition, construction, reconstruction and
rehabilitation of laboratory space;
(ii) capital equipment purchases;
(iii) specialized supplies purchases;
and
(iv) working capital to cover
costs of professional staff critical to the research to be undertaken by the
principal investigator (including staff scientists, postdoctoral fellows and
technicians, but excluding the principal investigator).
(2) The corporation may determine not to
reimburse eligible expenses if the award recipient fails to maintain its
required level of match during a specific grant disbursement period.
(3) Program grants shall not duplicate
payments received, or receivable, from other sources.
(h)
Reporting requirements.
(1) The corporation is required by statute to
submit to the Governor, the temporary president of the New York State Senate,
and the speaker of the New York State Assembly an annual report on the
operations and accomplishments of the life sciences initiatives programs on or
before October 1st annually. The report must include, but is not limited to,
information and statistics detailing the economic impact of the activities
undertaken with program funds; the number and amount of Federal funds procured
after an investment of program funds; jobs created and maintained after receipt
of program funds; and the average salaries of such jobs created and
maintained.
(2) The corporation
will establish periodic reporting requirements for program grantees to provide
information to the corporation so that the corporation may accomplish its
statutory reporting obligations. These reporting obligations may extend beyond
the completion of the project for a period of three years.
(3) Failure by a grantee to provide the
required information in a manner that is timely and otherwise satisfactory to
the corporation may subject the grant to full or partial recapture.
The amended version of this section by
New
York State Register December 22, 2021/Volume XLIII, Issue 51,
eff. 12/22/2021